Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way-Reference-Cited by-同舟云学术

Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way

Published:2022-06 Issue:6 Volume:14 Page:
ISSN:1674-2788
Container-title:Journal of Molecular Cell Biology
language:en
Short-container-title:

Author:

Chaves Otávio Augusto¹²,Sacramento Carolina Q¹²,Fintelman-Rodrigues Natalia¹²,Temerozo Jairo Ramos³⁴^ORCID,Pereira-Dutra Filipe¹^ORCID,Mizurini Daniella M⁵,Monteiro Robson Q⁵,Vazquez Leonardo¹²,Bozza Patricia T¹,Castro-Faria-Neto Hugo Caire¹,Souza Thiago Moreno L¹²

Affiliation:

1. Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil

2. National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil

3. National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil

4. Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz) , Rio de Janeiro, RJ , 21040-900, Brazil

5. Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro (UFRJ) , Rio de Janeiro, RJ , 21941-590, Brazil

Publisher

Oxford University Press (OUP)

Subject

Cell Biology,Genetics,Molecular Biology,General Medicine

Link

https://academic.oup.com/jmcb/advance-article-pdf/doi/10.1093/jmcb/mjac039/44266695/mjac039.pdf

Reference10 articles.

1. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19;Adam;Blood Adv.,2021

2. Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach;Biembengut;Mem. Inst. Oswaldo Cruz,2020

3. Apixaban: a clinical pharmacokinetic and pharmacodynamic review;Byon;Clin. Pharmacokinet.,2019